Purpose: Heat shock factor 1 (HSF1) is a key regulator of the heat shock response and plays an important role in various cancers. However, the role of HSF1 in gastric cancer is still unknown. The present study evaluated the function of HSF1 and related mechanisms in gastric cancer.
INTRODUCTION
Worldwide, gastric cancer incidence ranks second among men and third among women, and the cancer is the second leading cause of cancer-related deaths. [1] [2] [3] Despite greater understanding of genetic and epigenetic various cancer events, the absence of biomarkers for identification of gastric cancer has remained a problem. 4 Also, among various anti-cancer therapies for gastric cancer, chemotherapy, which is the most common therapy, shows limited efficacy. 5 Therefore, identifying prognosis marker and targeted therapy for gastric cancer may improve the survival of advanced gastric cancer patients. 6 Although many studies have suggested the involvement of various molecular signaling pathways in gastric tumorigenesis and related prognostic markers or therapeutic targets, the actual molecular mechanisms thereof have not been fully elucidated. 7, 8 Therefore, reliable and feasible prognostic markers or therapeutic targets for gastric cancer remain an unmet need.
Heat shock factor 1 (HSF1) is a key transcription factor that
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Seok-Jun Kim 1 initiates the expression of heat shock proteins (HSPs) by binding to consensus motifs, such as heat shock elements and other genes, in response to cellular stress, thereby allowing the cell to adapt and prolong survival. HSPs, such as HSP27, HSP70, and HSP90, are important chaperone proteins that promote proper folding, transportation, and degradation of proteins within cells. [9] [10] [11] [12] HSF1 activation is repressed by interaction with overexpressed HSP in non-tumor cells. [9] [10] [11] [12] [13] However, this feedback inhibition may be ineffective in tumor cells. Several studies have linked increased HSF1 activity to malignant cell growth. 9 This pro-malignant activity is induced upon the binding of HSF1 to the promoters and the subsequent initiation of the expression of certain genes independent of heat shock. 11, 14 Several studies have demonstrated that HSF1 is overexpressed in solid tumor cancers, including esophageal squamous cell, breast, hepatocellular, osteosarcoma, non-small cell lung, and pancreatic cancer. [15] [16] [17] [18] Furthermore, evidence implies that the elevated expression of HSF1 is correlated with poor survival in patients with cancer. 18 We prepared HSF1-expressing gastric cancer cells and studied their proliferation and motility and evaluated HSF1 expression. The same experiments were extended in tissues from patients with gastric cancer to determine the clinical significance of HSF1 expression in gastric cancer.
MATERIALS AND METHODS

Cell culture
The human gastric cancer cell lines AGS and MKN28 were obtained from the Korean Cell Line Bank (Seoul, Korea) and cultured in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) at 37°C in a humidified incubator with a 5% CO2 atmosphere.
Cell proliferation assay
AGS and MKN28 cells were plated in 96-well plates (3×10 3 cells/well). After incubation for 24 hours, the cells were transfected with siRNA (scRNA or HSF1 siRNA) and vector plasmid (pcDNA_EV or pcDNA_HSF1). WST-1 solution (Daeil Lab Services Co., Ltd, Seoul, Korea) was added to each well 48 hours after transfection. The plates were incubated for another 1-2 hours and gently shaken. Absorbance was then measured at a wavelength of 450 nm.
Transwell migration and invasion assays
AGS and MKN28 cells were transfected with siRNA (scRNA or HSF1 siRNA) and vector plasmid (pcDNA_EV or pcDNA_ HSF1). After 24-hour transfection, 1×10 4 cells from each well were isolated and added to the upper transwell chamber (Corning Costar, Tewksbury, MA, USA) that carried a filter coated with 0.5 mg/mL of collagen type I (BD Biosciences, Seoul, Korea) for the migration assay or a filter coated with Matrigel (1:15) (BD Biosciences) for the invasion assay. RPMI-1640 containing 10% FBS and 1% antibiotics was added to the lower chamber, and the plates were incubated for 20 hours. Cells that migrated and invaded were quantified after hematoxylin and eosin staining, as previously described. 18 For quantification, cells were counted in five randomly selected areas of each well using wide-field microscopy. Data are expressed as mean±SEM from three independent experiments.
Transfection of siRNA and HSF1 construction
Transfection of human HSF1 siRNAs or scRNA was performed using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's protocol. The coding strands of HSF1 siRNAs purchased from Genolution Inc. (Seoul, Korea) were as follows: 1) 5'-GAACGACAGUGGCUCAGCAUU-3' and 2) 5'-CCACUUGGAUGCUAUGGACUU-3'. Human HSF1 was cloned into the pcDNA-3.0-Flag plasmid between EcoR1 and Xho1 restriction enzyme sites to obtain the pcDNA_HSF1 construct. The full-length HSF1 cDNA was amplified with polymerase chain reaction (PCR) using the primers 5'-GAATTCA TGGATCTGCCCGTGGGCCC-3' (sense) and 5'-CTCGAG CTAGGAGACAGTGGGGTCCT-3' (antisense). The clone for HSF1 cDNA was provided by the Korea Human Gene Bank (Medical Genomics Research Center, KRIBB, Daejeon, Korea).
RNA isolation and reverse transcription-polymerase chain reaction
Total RNA was extracted from human gastric cancer cells and tissues obtained from patients using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. Reverse transcription (RT) was carried out using a RT system (Toyobo, Osaka, Japan), and PCR was performed using Ex-Taq DNA Polymerase (Takara Bio Inc, Shiga, Japan). The primer sequences were as follows: HSF1, 5'-GACATAAAGATCCGCCAGGA-3' (sense) and 5'-CTGCACCAGTGAGATCAGGA-3' (antisense); β-actin: 5'-AGCCTCGCCTTTGCCGA-3' (sense) and 5'-CTGGTGCCT GGGGCG-3' (antisense).
Western blot analysis
Western blot analysis was carried out as described previously. 19 Briefly, AGS and MKN28 cells were lysed by radioimmunoprecipitation assay buffer (Biosesang Inc, Seongnam, Korea) containing a protease inhibitor cocktail and phosphatase inhibitor cocktail (GeneDEPOT, Barker, TX, USA), followed by sonication on ice. A total of 20 μg of protein was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane (Merck, Kenilworth, NJ, USA). After blocking with 5% skim milk for 1 hour, the membrane was incubated overnight with anti-HSF1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) primary antibody in 5% bovine serum albumin at 4°C. Anti-β-actin (Santa Cruz Biotechnology) was used as a control. The membrane was then incubated with a secondary antibody (goat-anti-rabbit IgG) for 90 min, followed by detection of protein bands with an enhanced chemiluminescence kit (BioRad, Hercules, CA, USA) using Supernova-Q1800.
Human gastric cancer tissue microarray analyses
For immunohistochemical (IHC) analysis, core tissue biopsy specimens (2-mm diameter) were obtained from individual paraffin-embedded gastric carcinomas (donor blocks) and arranged in new recipient paraffin blocks (tissue array blocks) using a trephine apparatus (SuperBioChips Laboratories, Seoul, Korea). IHC analysis of HSF1 was performed as described previously. 20 Immunohistochemistry of HSF1 revealed nuclear positivity and no cytoplasmic reaction in either normal mucosa cell or gastric cancer cells. The intensity of HSF1 staining was initially scored from 0 to 3 as follows: 0, no nuclear staining; 1, weak; 2, moderate; and 3, strong nuclear positivity. No gastric cancer samples were negative for HSF1 immunohistochemistry. Then, gastric cancer samples were grouped into those with staining intensities of 1-2 (low expression) and 3 (high expression) for statistical correlation and survival rate calculation.
Gene expression profiles using cDNA microarray data and analysis of public dataset GSE13861, GSE13195, and GSE30727, as available datasets, were downloaded from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). GSE13861 was developed from 65 primary gastric adenocarcinomas, six gastrointestinal stromal tumors, and 19 surrounding normal fresh frozen tissues. GSE13195 and GSE30727 were developed, respectively, from 25 pairs and 30 matching pairs of gastric cancer and normal surrounding tissue. These three datasets were nor- malized using GEO2R, and a scatter plot for the expression pattern analysis was obtained.
Kaplan-Meier analysis of overall survival
Kaplan-Meier analysis of overall survival for patients with gastric cancer was performed using the online resource KaplanMeier Plotter, as a public database (http://kmplot.com/analysis). 21 To investigate the prognostic value of HSF1, the patient cohorts were divided into two groups according to their median (or upper/lower quartile) expression of HSF1, and the database was analyzed by a PostgreSQL server (https://www. postgresql.org/about/servers/). The two patient cohorts were compared by a Kaplan-Meier survival plot, and hazard ratios with 95% confidence intervals and log rank p values were calculated.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). The data were analyzed by Student's t-test and one-way ANOVA, unless otherwise specified. Differences in patient survival were determined using the Kaplan-Meier method. Results are presented as a mean±SEM. Values of p<0.05 were considered statistically significant.
RESULTS
Analysis of HSF1 expression and survival rate using cDNA microarray data in gastric cancer patients First, we aimed to identify relationships between high expression of HSF1 and poor survival in gastric cancer using the GEO database (Fig. 1A-C) and Kaplan-Meier analysis for gastric cancer patients (Fig. 1D) . We collected three (GSE13861, GSE13195, and GSE30727) public datasets of patients with gastric cancer and compared the expression levels of HSF1 in tumor and normal gastric tissues (Fig. 1A-C) . In all three datasets, the expression of HSF1 was higher in tumor tissue than in normal tissue. Expression was found to be statistically significant in two of the datasets ( Fig. 1A and B; p<0.001) . Fig. 1C depicts a trend in higher expression of HSF1 in tumor tissues than in normal tissues (p=0.061). Furthermore, statistical analysis of tumor tissue from the public database of patients with gastric cancer revealed a correlation between high expression of HSF1 and a significantly lower probability of survival (Fig. 1D) .
HSF1 protein expression upregulated in patients with gastric cancer and correlated with poor survival
To determine HSF1 protein expression levels in patients with gastric cancer, a tissue microarray (TMA) of 54 patients was prepared and IHC analysis was performed (Table 1 and Fig.  2A ). High expression of HSF1 was detected in tumor tissues from the patients with intestinal and diffuse types of gastric cancer, and most HSF1 expression was localized in the nucleus. HSF1 expression was notably upregulated in tumor tissues from patients with gastric cancer (Fig. 2A) . Quantitative analysis of HSF1 staining confirmed that patients with gastric cancer exhibited higher expression of HSF1 in tumor tissues than in normal tissues (Fig. 2B) . As shown in Table 1 , the expression levels of HSF1 were analyzed with respect to clinical factors. Based on the expression level of HSF1, gastric cancer tissues were further classified as high (score 3) and low (score 1 and 2) groups. TMA results confirmed the absence of any significant correlation between HSF1 expression and clinicopathological findings (Table 1) . However, the expression of HSF1 was significantly higher in tumor tissue than in the paired normal tissue in patients with gastric cancer (Fig. 2B) . The probability of survival was significantly lower for patients with gastric cancer exhibiting high HSF1 expression levels in tumor tissues (Fig. 2C) . These data strongly indicate that HSF1 expression is upregulated during the progression of gastric cancer. 
Knockdown of HSF1 reduces the proliferation, migration, and invasion of gastric cancer cells
We have previously confirmed the overexpression of HSF1 protein in gastric cancer cell lines. 20 We examined the effects of loss-and gain-of-function of HSF1 in AGS and MKN28 cells by evaluating the mRNA and protein expressions of HSF1 (Fig.  3A) . The mRNA and protein expressions of HSF1 were knocked down with two specific siRNAs, and the efficiency of interference was confirmed by RT-PCR and Western blot analysis (Fig. 3A) . After the knockdown of HSF1, cell proliferation was analyzed by WST assay. As a result, we found that the knockdown of HSF1 expression significantly reduced the proliferation of gastric cancer cells (Fig. 3B) . Transwell migration and invasion assays showed that HSF1 knockdown inhibited the migration and invasion of gastric cancer cells (Fig. 3C and D) . These results indicate that HSF1 induces the progression of gastric cancer. Comparative analysis of HSF1 expression in normal and tumor tissues from patients with gastric cancer based on staining intensity. p values were calculated using Student's t-test and significant differences are indicated by * (*p<0.001). (C) Kaplan-Meier analysis of survival curves for patients with gastric cancer according to the expression of HSF1 in tumor tissues (n=54). HSF1 high-expression group (score 3) had a much lower survival rate at 125 months than the HSF1 low-expression group (score 1 or 2). HSF1, heat shock factor 1.
Overexpression of HSF1 induces proliferation, migration, and invasion of gastric cancer cells
The effects of the gain-of-function of HSF1 in AGS and MKN28 gastric cancer cells were examined. The cells were transiently transfected with a HSF1 overexpression vector or empty vector for 48 hours. Overexpression of HSF1 was confirmed by RT-PCR and Western blot analysis (Fig. 4A) . Overexpression of HSF1 significantly increased gastric cancer cell proliferation (Fig. 4B) , migration (Fig. 4C) , and invasion (Fig. 4D ). These findings suggest that HSF1 participates in the progression of gastric cancer.
DISCUSSION
Our study demonstrated that the silencing of HSF1 expression results in a reduction in the proliferation, migration, and invasion of gastric cancer cells, while HSF1 overexpression elicits the opposite effects on gastric cancer cells. Furthermore, the high expression of HSF1 was found to be correlated with poor prognosis in patients with gastric cancer. HSF1 regulates the expression of HSPs by binding to consensus motifs, such the heat shock elements. HSPs are highly conserved stress proteins that are expressed and induced in response to heat shock or other stress factors or unfavorable conditions, such as inflammation, ischemia, infection, or carcinogenesis. 12, 22, 23 In gastric cancer, HSP70 has been reported as a high-risk factor, and HSP90 inhibitor has been used for therapeutic purposes. 24, 25 We previously reported that HSF1 regulates neogenin-1 expression to promote motility of gastric cancer cells by binding with galectin-3. 20 These studies show that HSP and HSF1 contribute to the tumorigenesis or progression of gastric cancer. However, the role of HSF1 in gastric cancer has remained unclear.
The protein HSF1 was recently shown to play a significant role in the development and progression of a variety of cancers. 9 In particular, HSF1 was described as playing an essential role in the development of lymphoma in p53-deficient mouse and carcinomas in a Ras tumor model. 26, 27 In hepatocellular carcinoma (HCC), HSF1 has been found to directly activate miR-135b expression and to promote HCC cell motility. 28 Furthermore, IHC analysis has revealed HSF1 as a prognostic marker for breast cancer. 15, 29 High level expression of HSF1 was also reported in cervical, colon, lung, pancreatic, osteosarcoma, and prostate cancers. 16, 18, 30, 31 These studies suggest that HSF1 may serve as a key regulator of tumorigenesis in a variety of cancers, including breast cancer.
Using three sets of GEO datasets, our study confirmed increased levels of HSF1 mRNA expression in tumor tissues from patients with gastric cancer. Furthermore, the high level of HSF1 expression was correlated with poor overall survival. We confirmed the protein expression level of HSF1 in 54 tumor samples from patients with gastric cancer and found that the expression level of HSF1 protein was consistent with the ex- . p values were calculated using ANOVA and statistically significant differences are indicated as * (*p<0.001). HSF1, heat shock factor 1.
pression levels of HSF1 mRNA. Although we observed no significant correlation between HSF1 expression and clinicopathological findings, HSF1 expression was increased in tumor tissues and was correlated with poor overall survival. To determine whether HSF1 expression is important for tumor growth and cell motility, we performed loss-of-function and gain-of-function analyses in gastric cancer cells. Downregulation of HSF1 significantly delayed the growth and motility of gastric cancer cells, while the overexpression of HSF1 increased cell growth and motility. Further studies evaluating the role of HSF1 in gastric cancer using large scale clinical data are warranted.
In conclusion, the present study demonstrated increases in the expression levels of HSF1 in gastric cancer tissues, compared to paired normal tissue. We deemed that HSF1 promotes the proliferation, migration, and invasion of gastric cancer cells and confirmed that HSF1 expression is correlated with poor prognosis in patients with gastric cancer. Thus, our study documents the essential role of HSF1 in gastric cancer progression, suggesting its potential role as a prognostic maker for gastric cancer. 
